Endo's parent company is looking to change its name and will integrate four of its operating units, the drug maker said Thursday.

Profits for Endo Pharmaceutical Holdings rose to $54.6 million during second quarter 2011, up 6% from $51.5 million in second quarter 2010, the drug maker said.

Endo Pharmaceuticals has acquired a provider of devices and therapies for male and female pelvic health.

Endo's board of directors has expanded to nine members with the addition of David Nash.

The Food and Drug Administration has approved a topical testosterone replacement therapy made by Endo Pharmaceuticals, Endo said last week.

Strong generic sales helped Endo edge analyst expectations for the third quarter, the company noted....

Endo Pharmaceuticals will acquire generic drug maker Qualitest Pharmaceuticals for $1.2 billion, Endo said Tuesday....

Endo Pharmaceuticals has completed its acquisition of a company that provides urological products and services,...